Immuneering Signs Supply Deal with Lilly for Ongoing Cancer Drug Trials

Immuneering has signed a clinical supply agreement with Eli Lilly to test its cancer drug olomorasib in combination with atebimetinib. The agreement will facilitate the evaluation of Immuneering's lead candidate, atebimetinib, and the combination will be tested.

Immuneering Corporation and Eli Lilly and Company have entered into a clinical supply agreement to evaluate the combination of Immuneering's lead product candidate, atebimetinib (IMM-1-104), and Eli Lilly's second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The agreement supports a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.

The collaboration marks the second such agreement for Immuneering this year, as the company seeks to explore the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. E.B. Brakewood, Chief Business Officer of Immuneering, stated, "This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC" [1].

The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway, supported by preclinical studies showing enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy. Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering, commented, "The combination of atebimetinib and olomorasib has the potential to improve outcomes in a population with limited effective treatment options" [1].

Immuneering will maintain global development and commercialization rights to atebimetinib. The company's lead product candidate is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer [1].

This agreement follows Immuneering's February 2025 announcement of a clinical trial agreement with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with the anti-PD-1 therapy Libtayo® (cemiplimab) in patients with advanced non-small cell lung cancer [2].

References:
[1] https://drug-dev.com/immuneering-announces-clinical-supply-agreement-with-lilly-to-evaluate-atebimetinib-in-combination-with-olomorasib/
[2] https://www.globenewswire.com/news-release/2025/08/25/3138395/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Lilly-to-Evaluate-Atebimetinib-in-Combination-with-Olomorasib.html